First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J

Open source

DOI: 10.1038/s41591-024-03450-4
Published: 2025 Apr
Container: Nature medicine
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-024-03450-4,
  title = {First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.},
  author = {Shen L and Zhang Y and Li Z and Zhang X and Gao X and Liu B and Wang Y and Ba Y and Li N and Zhang R and Zhang J and Chen Y and Chen J and Huang M and Fu Y and Liu M and Liu Z and Zhao J and Li W and Wei J and Li C and Xu N and Guo Z and Cao B and Liu L and Nie P and Wan L and Sheng L and Liu Z and He Y and Gu K and Wu G and Wang W and Zhang F and Qiu W and Guo J and Ying J and Pan H and Xu H and Yuan Y and Bai Y and Wang Z and Xu J and Zhao X and Liu H and Zhang X and Dai W and Xu H and Liu M and Xie L and Tang Y and Jin J and Qu X and Fang X and Huang M and Chen H and Zheng Z and Wang Y and Wang D and Li X and Yu G and Liu H and Zhou Y and Zhong D and Zeng S and Kang M and Wang M and Gao Y and Li W and Wang Z and Zhang M and Zhang J and Li Q and Sun S and Zang A and Lin L and Xie M and Zhuang Z and Zhang T and Yao Z and Lu D and Liu W and Hu M and Wang ZM and Li B and Xia M and Zhang J and Ying X and Pardoll DM and Ji J},
  year = {2025},
  journal = {Nature medicine},
  doi = {10.1038/s41591-024-03450-4},
  url = {https://doi.org/10.1038/s41591-024-03450-4}
}

RIS

TY  - JOUR
TI  - First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
AU  - Shen L
AU  - Zhang Y
AU  - Li Z
AU  - Zhang X
AU  - Gao X
AU  - Liu B
AU  - Wang Y
AU  - Ba Y
AU  - Li N
AU  - Zhang R
AU  - Zhang J
AU  - Chen Y
AU  - Chen J
AU  - Huang M
AU  - Fu Y
AU  - Liu M
AU  - Liu Z
AU  - Zhao J
AU  - Li W
AU  - Wei J
AU  - Li C
AU  - Xu N
AU  - Guo Z
AU  - Cao B
AU  - Liu L
AU  - Nie P
AU  - Wan L
AU  - Sheng L
AU  - Liu Z
AU  - He Y
AU  - Gu K
AU  - Wu G
AU  - Wang W
AU  - Zhang F
AU  - Qiu W
AU  - Guo J
AU  - Ying J
AU  - Pan H
AU  - Xu H
AU  - Yuan Y
AU  - Bai Y
AU  - Wang Z
AU  - Xu J
AU  - Zhao X
AU  - Liu H
AU  - Zhang X
AU  - Dai W
AU  - Xu H
AU  - Liu M
AU  - Xie L
AU  - Tang Y
AU  - Jin J
AU  - Qu X
AU  - Fang X
AU  - Huang M
AU  - Chen H
AU  - Zheng Z
AU  - Wang Y
AU  - Wang D
AU  - Li X
AU  - Yu G
AU  - Liu H
AU  - Zhou Y
AU  - Zhong D
AU  - Zeng S
AU  - Kang M
AU  - Wang M
AU  - Gao Y
AU  - Li W
AU  - Wang Z
AU  - Zhang M
AU  - Zhang J
AU  - Li Q
AU  - Sun S
AU  - Zang A
AU  - Lin L
AU  - Xie M
AU  - Zhuang Z
AU  - Zhang T
AU  - Yao Z
AU  - Lu D
AU  - Liu W
AU  - Hu M
AU  - Wang ZM
AU  - Li B
AU  - Xia M
AU  - Zhang J
AU  - Ying X
AU  - Pardoll DM
AU  - Ji J
PY  - 2025
JO  - Nature medicine
DO  - 10.1038/s41591-024-03450-4
UR  - https://doi.org/10.1038/s41591-024-03450-4
ER  -

APA

L, S., Y, Z., Z, L., X, Z., X, G., B, L., Y, W., Y, B., N, L., R, Z., J, Z., Y, C., J, C., M, H., Y, F., M, L., Z, L., J, Z., W, L., J, W., C, L., N, X., Z, G., B, C., L, L., P, N., L, W., L, S., Z, L., Y, H., K, G., G, W., W, W., F, Z., W, Q., J, G., J, Y., H, P., H, X., Y, Y., Y, B., Z, W., J, X., X, Z., H, L., X, Z., W, D., H, X., M, L., L, X., Y, T., J, J., X, Q., X, F., M, H., H, C., Z, Z., Y, W., D, W., X, L., G, Y., H, L., Y, Z., D, Z., S, Z., M, K., M, W., Y, G., W, L., Z, W., M, Z., J, Z., Q, L., S, S., A, Z., L, L., M, X., Z, Z., T, Z., Z, Y., D, L., W, L., M, H., ZM, W., B, L., M, X., J, Z., X, Y., DM, P., & J, J. (2025). First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.. Nature medicine. https://doi.org/10.1038/s41591-024-03450-4

Source records

pubmed · retrieved 2026-09-27T07:44:37.348Z
europe-pmc · retrieved 2026-09-27T07:44:37.364Z